| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000015363 |
| Receipt No. | R000017879 |
| Official scientific title of the study | ILM Blue assisted membrane peeling in vitrectomy |
| Date of disclosure of the study information | 2014/11/15 |
| Last modified on | 2016/04/07 (Ver. 8) |
| Basic information | ||
| Official scientific title of the study | ILM Blue assisted membrane peeling in vitrectomy | |
| Title of the study (Brief title) | ILM Blue assisted membrane peeling in vitrectomy | |
| Region |
|
|
| Condition | ||
| Condition | macular hole, epiretinal membrane, macular edema, retinoschisis, retinal detachment | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | to evaluate the safety and the efficacy of ILM Blue assisted membrane peeling |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | the frequency and the content of adverse effects |
| Key secondary outcomes | visual acuity change in 1, 3, and 12 months after surgery
visual field change in 3 and 12 months after surgery the quality of ILM staining the rate of complete ILM peeling the rate of macular hole |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | ILM staining with ILM Blue | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | the diagnosis of macular hole, macular edema, epiretinal membrane, retinoschisis, or retinal detachment by slit lamp microscopy, fundusscopy, and optical coherence tomography.
And required surgical treatment. |
|||
| Key exclusion criteria | 1.2 or better of visual acuity
the patients with glaucoma younger than 20 years old, nursing women, pregnancy |
|||
| Target sample size | 150 | |||
| Research contact person | |
| Name of lead principal investigator | Suzuma Kiyoshi |
| Organization | Kyoto University Graduate School of Medicine |
| Division name | Department of Ophthalmology and Visual Science |
| Address | 54ShogoinKawaharacho, Sakyo, Kyoto, Japan |
| TEL | 075-751-3248 |
| suzuma@kuhp.kyoto-u.ac.jp | |
| Public contact | |
| Name of contact person | Ai Higashiyama |
| Organization | Kyoto University Graduate School of Medicine |
| Division name | Department of Ophthalmology and Visual Science |
| Address | 54ShogoinKawaharacho, Sakyo, Kyoto, Japan |
| TEL | 075-751-3250 |
| Homepage URL | |
| ahigashi@kuhp.kyoto-u.ac.jp | |
| Sponsor | |
| Institute | Kyoto University Graduate School of Medicine, Department of Ophthalmology and Visual Science |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | donation money for research |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-bin/icdr_e/ctr_view.cgi?recptno=R000017879 |